Rapamycin and MPA, but not CsA, impair human NK Cell cytotoxicity due to differential effects on NK cell phenotype

American Journal of Transplantation

Volumn 10, Issue 9, 2010, Pages 1981-1990

  Eissens, D N ^a   Van Der Meer, A ^a   Van Cranenbroek, B ^a   Preijers, F W M B ^a   Joosten, I ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cytokines; cytotoxicity; immunosuppression; NK cells; transplantation

Indexed keywords

CD56 ANTIGEN; CYCLOSPORIN A; GAMMA INTERFERON; MYCOPHENOLIC ACID; RAPAMYCIN;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL;

ANTIGENS, CD56; CELL PROLIFERATION; CELLS, CULTURED; CYCLOSPORINE; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; KILLER CELLS, NATURAL; MYCOPHENOLIC ACID; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY C; PHENOTYPE; RECEPTORS, NATURAL KILLER CELL; SIROLIMUS; TISSUE DISTRIBUTION;

EID: 77956167822     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03242.x     Document Type: Article

References (34)

1. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990 76 : 2421 2438.
2. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989 47 : 187 376.
3. Cook MA, Milligan DW, Fegan CD et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004 103 : 1521 1526.
4. Giebel S, Nowak I, Wojnar J et al. Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation. Transplant Proc 2006 38 : 287 291.
5. Ruggeri L, Capanni M, Urbani E et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002 295 : 2097 2100.
6. Ruggeri L, Capanni M, Casucci M et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999 94 : 333 339.
7. Eissens DN, Schaap NP, Preijers FW et al. CD3(+)/CD19(+)-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. Leukemia 2010 24 : 583 591.
8. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005 5 : 201 214.
9. Braud VM, Allan DS, O'Callaghan CA et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998 391 : 795 799.
10. Moretta A, Bottino C, Vitale M et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001 19 : 197 223.
11. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Rev 2006 20 : 123 137.
12. Papamichail M, Perez SA, Gritzapis AD, Baxevanis CN. Natural killer lymphocytes: Biology, development, and function. Cancer Immunol Immunother 2004 53 : 176 186.
13. Cutler C, Li S, Ho VT et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007 109 : 3108 3114.
14. Haentzschel I, Freiberg-Richter J, Platzbecker U et al. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant 2008 42 : 113 120.
15. Schleuning M, Judith D, Jedlickova Z et al. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: An observational cohort study. Bone Marrow Transplant 2008 43 : 717 723.
16. Vogelsang GB, Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: Preliminary findings. Bone Marrow Transplant 2001 27 : 1255 1262.
17. Neumann F, Graef T, Tapprich C et al. Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant 2005 35 : 1089 1093.
18. Introna M, Allavena P, Spreafico F, Mantovani A. Inhibition of human natural killer activity by cyclosporin A. Transplantation 1981 31 : 113 116.
19. Kosugi A, Shearer GM. Effect of cyclosporin A on lymphopoiesis. III. Augmentation of the generation of natural killer cells in bone marrow transplanted mice treated with cyclosporin A. J Immunol 1991 146 : 1416 1421.
20. Petersson E, Qi Z, Ekberg H, Ostraat O, Dohlsten M, Hedlund G. Activation of alloreactive natural killer cells is resistant to cyclosporine. Transplantation 1997 63 : 1138 1144.
21. Wang H, Grzywacz B, Sukovich D et al. The unexpected effect of cyclosporin A on CD56+CD16-and CD56+CD16+ natural killer cell subpopulations. Blood 2007 110 : 1530 1539.
22. Wai LE, Fujiki M, Takeda S, Martinez OM, Krams SM. Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. Transplantation 2008 85 : 145 149.
23. Lin SJ, Kuo ML. Effect of cyclosporin A on interleukin-15-activated umbilical cord blood natural killer cell function. Cytotherapy 2008 10 : 397 405.
24. Shapira MY, Hirshfeld E, Weiss L et al. Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model. Cancer Immunol Immunother 2005 54 : 383 388.
25. Bornhauser M, Schuler U, Porksen G et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999 67 : 499 504.
26. Cutler C, Kim HT, Hochberg E et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2004 10 : 328 336.
27. Jenke A, Renner U, Richte M et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant 2001 15 : 176 184.
28. Kagawa Y, Sawada J, Yamada S et al. Relationship between development of nephrotoxicity and blood concentration of cyclosporine A in bone-marrow transplanted recipients who received the continuous intravenous infusion. Biol Pharm Bull 2003 26 : 1115 1119.
29. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer cell subsets. Trends Immunol 2001 22 : 633 640.
30. Borrego F, Robertson MJ, Ritz J, Pena J, Solana R. CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology 1999 97 : 159 165.
31. Bethge WA, Haegele M, Faul C et al. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: Fast engraftment and low toxicity. Exp Hematol 2006 34 : 1746 1752.
32. Kim DH, Sohn SK, Lee NY et al. Transplantation with higher dose of natural killer cells associated with better outcomes in terms of non-relapse mortality and infectious events after allogeneic peripheral blood stem cell transplantation from HLA-matched sibling donors. Eur J Haematol 2005 75 : 299 308.
33. Yang YG, Wang H, Asavaroengchai W, Dey BR. Role of Interferon-gamma in GVHD and GVL. Cell Mol Immunol 2005 2 : 323 329.
34. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK cell cytokine and chemokine productionby target cell recognition. Blood 2010 115 : 2167 2176.